# name
State-of-the-art in host-derived biomarkers of Chagas disease prognosis and early evaluation of anti-Trypanosoma cruzi treatment response

# metadata.dc.description.abstract[].value
Chagas disease is caused by infection with the parasite
                Trypanosoma cruzi, which might lead to a chronic disease state
                and drive to irreversible damage to the heart and/or digestive
                tract tissues. Endemic in 21 countries in the Americas, it is
                the neglected disease with a highest burden in the region.
                Current estimates point at ~6 million people infected, of which
                ~30% will progress onto the symptomatic tissue disruptive stage.
                There is no vaccine but there are two anti-parasitic drugs
                available: benznidazole and nifurtimox. However, their efficacy
                is variable at the chronic symptomatic stage and both have
                frequent adverse effects. Since there are no prognosis markers,
                drugs should be administered to all T. cruzi-infected
                individuals in the indeterminate and early symptomatic stages.
                Nowadays, there are no tests-of-cure either, which greatly
                undermines patients' follow-up and the search of safer and more
                efficacious drugs. Therefore, the identification and validation
                of biomarkers of disease progression and/or treatment response
                on which to develop tests of prognosis and/or cure is a major
                research priority. Both parasite- and host-derived markers have
                been investigated. In the present manuscript we present an
                updated outlook of the latter.

# metadata.dc.relation.ispartof[].value
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2020, vol. 1886, num. 7

# metadata.dc.source[].value
Articles publicats en revistes (ISGlobal)

# metadata.dc.title[].value
State-of-the-art in host-derived biomarkers of Chagas disease prognosis and early evaluation of anti-Trypanosoma cruzi treatment response